- Accesswire•10 days ago
BRISBANE, CA / ACCESSWIRE / February 13, 2017 / KaloBios Pharmaceuticals, Inc. (OTC PINK: KBIO), a biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases, ...
- GlobeNewswire•10 days ago
BRISBANE, Calif., Feb. 13, 2017-- KaloBios Pharmaceuticals, Inc., a biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases, announced that Cameron Durrant, ...
- GlobeNewswire•14 days agoPomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Securities of KaloBios Pharmaceuticals, Inc. -- KBIO
SAN JOSE, Calif., Feb. 09, 2017-- Pomerantz LLP announces that the United States District Court for the Northern District of California has approved the following announcement of a proposed partial class ...
KBIO : Summary for KALOBIOS PHARMACEU COM USD0.001 - Yahoo Finance
KaloBios Pharmaceuticals, Inc. (KBIO)
Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
|Day's Range||2.76 - 3.00|
|52 Week Range||2.17 - 5.21|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-0.55|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|